OncoMatch/Clinical Trials/NCT06492616
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Is NCT06492616 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for breast cancer.
Treatment: Elacestrant · Anastrozole · Letrozole · Exemestane · Tamoxifen — The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 overexpression (ER-positive, ≥ 10% by IHC) (≥ 10% by IHC)
ER-positive (≥ 10% by immunohistochemistry [IHC])
Required: HER2 (ERBB2) negative (IHC = 0, 1+, 2 and ISH-negative) (IHC = 0, 1+, 2 and ISH-negative)
HER2-negative [IHC = 0, 1+, 2 and in situ hybridization [ISH]-negative)]
Prior therapy
Must have received: endocrine therapy (aromatase inhibitor, tamoxifen) — adjuvant
Participants who have received at least 24 months but not more than 60 months of endocrine therapy (AIs or tamoxifen)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Southern Cancer Center, PC · Daphne, Alabama
- Ironwood Cancer and Research Centers · Chandler, Arizona
- Banner MD Anderson Cancer Center · Gilbert, Arizona
- Mayo Clinic · Scottsdale, Arizona
- Arizona Clinical Research Center, Inc. · Tucson, Arizona
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify